Avacta Group PLC - Leeds, England-based cancer therapies - Announces approval of its investigation new drug application for AVA6000 by the US Food & Drug Administration. This will allow the company to expand its Phase 1 clinical trial, ALS-6000-101, into clinical trial sites in the US.
AVA6000 is a novel form of doxorubicin that has been modified with Avacta's Precision platform to improve its safety and therapeutic index. Anthracyclines such as doxorubicin, a generic chemotherapy, are widely used as part of standard of care in several tumour types.
Current stock price: 125.30 pence, up 4.4%
Year-to-date change: up 9.9%
By Greg Roxburgh; gregroxburgh@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Avacta Group (AVCT)